• Genmab reported late-stage Phase 1/2 RAINFOL-01 results for investigational ADC Rina-S in platinum-resistant ovarian cancer.
• Results were presented in a late-breaking oral session at the International Gynecologic Cancer Society Congress 2026.
• Study showed durable, clinically meaningful tumor responses in a heavily pretreated population, supporting the program’s risk-reward profile.
• Activity was seen across folate receptor alpha expression levels, widening the potential addressable market beyond high-expression patients.
• Genmab highlighted manageable tolerability, while four Phase 3 trials across ovarian and endometrial settings continue to advance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 202610031540BIZWIRE_USPR_____20261001_BW541371) on October 03, 2026, and is solely responsible for the information contained therein.